Zymeworks, ALX Oncology to evaluate zanidatamab-ALX148 combination
Category: #health  By Pankaj Singh  Date: 2020-11-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Zymeworks, ALX Oncology to evaluate zanidatamab-ALX148 combination

Zymeworks Inc., a clinical-stage biopharmaceutical company involved in developing multifunctional biotherapeutics has recently entered into a clinical collaboration with ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, to assess the combination of HER2-targeted bispecific antibody from Zymeworks named zanidatamab and ALX148, an advanced CD47 blocker from ALX Oncology for the treatment of advanced cases of HER2-expressing breast cancer.

As per the agreement, Zymeworks will apparently conduct an open label, multi-center Phase 1b study to assess the efficacy and safety of zanidatamab-ALX148 combination in two parts. The first part of the study will assess its safety, while the second part will evaluate its safety, tolerability and anti-tumor activity in separate groups of HER2-low breast cancer, HER2-positive breast cancer and non-breast HER2-expressing solid tumors subjects.

Meanwhile, Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology has stated that their collaboration with Zymeworks combines two promising next-generation anti-cancer agents, the HER2-targeted bispecific antibody and the CD47 blocker designed for safe use in combination to enhance clinical activity with several anti-cancer agents.The collaboration will combine promising anti-tumor activity of ALX148 with HER2-targeted therapy in patients with advanced HER2-positive gastric and gastroesophageal cancer, Pons added.

Reportedly, preliminary results of ALX148 Phase 1b study (ASPEN-01) were presented at 35th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer.ALX148 has been claimed to display positive initial clinical activity in solid tumors cases, where it showed required tolerance in combination with anti-HER2 specific antibody as well as chemotherapy, without reaching maximum levels of tolerated dose.

Source credits: https://www.businesswire.com/news/home/20201116005959/en/Zymeworks-and-ALX-Oncology-Announce-Clinical-Collaboration-Evaluating-Zanidatamab-with-the-CD47-Blocker-ALX148-in-Patients-with-Advanced-HER2%E2%80%91Expressing-Breast-Cancer



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Canada-based CloudMD buys CMD to expand medical database
Canada-based CloudMD buys CMD to expand medical database
By Pankaj Singh

CloudMD Software & Services Inc., a virtual medical care solutions provider based in Canada, has reportedly announced that it has completed the acquisition of the Canadian Medical Directory (CMD)- the nation’...

Collier’s Medical to offer HealthySole UVC units for infection control
Collier’s Medical to offer HealthySole UVC units for infection control
By Pankaj Singh

Collier’s Medical Equipment, a leading distributor of technologically-advanced medical equipment, has reportedly inked an agreement with HealthySole. This agreement has been geared towards the delivery of Healthy...

Western Union to offer money transfer services at Walmart U.S. stores
Western Union to offer money transfer services at Walmart U.S. stores
By Pankaj Singh

Walmart, an American retail chain, and Western Union, a financial service company, have recently announced a new collaboration deal. The agreement will allow the money transfer services of Western Union to be deployed ...